Health care practitioners utilize the United States-Food and Drug Administration (US-FDA) pregnancy categorization (A, B, C, D, X) for making decision on the appropriateness of certain medications during pregnancy. Many non US-FDA approved medications are registered and marketed in Saudi Arabia. However, these medications do not have an assigned pregnancy risk categorization like those approved in the US. The objective of this review is to evaluate, report, and categorize the foetal risk associated with non-US-FDA approved medications registered by the Saudi Food and Drug Authority (S-FDA) according to the US-FDA pregnancy risk categorization system. We identified 109 non-US-FDA approved medications in the Saudi National Formulary (SNF) as of October 2007. We searched for data on functional or anatomical birth defects or embryocidal-associated risk using different databases and references. An algorithm for risk assessment was used to determine a pregnancy risk category for each medication. Out of 93 eligible med-
Introduction
In the United States, there are almost six million pregnancies annually. On average, pregnant woman take three to five prescription medications during pregnancy. For pregnant women with chronic medical conditions, prescription medications might need to be continued during pregnancy (Meadows, 2001) . In Saudi Arabia and several other countries in the world, there is no readily available risk categorization that could guide medication prescribing during pregnancy (MOH health statistics book for 2008).
In one report, approximately 2-4% of newly born babies have some form of birth defects. Less than 1% is thought to be linked to exposure to medications during pregnancy. About 9% are thought to be related to maternal medical conditions while 20-25% apparently have a genetic basis. In general, about 65% of birth defects are of unknown origin (Webster and Freeman, 2001) .
In another study, pregnant women who were exposed to medications not considered teratogenic believed that their risk for major malformations was 24% (Doering et al., 2002) . These suspicions are fed by the thalidomide disaster back in the 1950s and 1960s. Many babies were born with severe upper and lower limb deformities to women who used thalidomide to treat pregnancy related nausea and vomiting. In the wake of thalidomide disaster, the US-FDA established strict criteria for approval of new medications, in addition to development of the pregnancy risk classification system in 1979 (Doering et al., 2002) . Several criticisms have been cited by experts when this system was applied to practice such as being confusing, primitive, and outdated. In December 2009, the US-FDA released a proposal to the public to amend its regulations pertaining to the risk description in products labelling during pregnancy and lactation that may eliminate the risk categorization and add more details on the foetal and mother risk (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/Labeling/ucm093310.htm). However, until the writing of this manuscript, the US-FDA continues to require risk categorization for newly approved medications and it is not clear whether this proposal will be approved without changes and if the risk categorization will be removed. This proposal was published in the public domain for the public and health care professionals to submit their comments to the US-FDA. Thus, the proposal may potentially receive several changes to its contents before it gets approved and becomes a regulation. Despite this, the current US-FDA regulations still require pregnancy risk categorization for the newly approved medications. For example, in January 2012, the US-FDA approved Ivacaftor (KalydecoÒ) for Cystic Fibrosis and assigned it a pregnancy risk category B. Furthermore, the US-FDA and even after its proposal in 2009 continues to change pregnancy risk categorization of previously marketed medications once new data are available. For example, topiramate pregnancy risk categorization was recently changed from C to D based on new evidence.
The US-FDA pregnancy risk categorization is the most widely used method of classification for medication use during pregnancy in Saudi Arabia. Other international categorization systems include the Australian pregnancy risk classification (Australian Drug Evaluation Committee Category), the Swedish Catalogue of Approved Drugs (FASS), and the German categorization system. To our knowledge, other national drug regulatory authorities do not have an official pregnancy risk categorization system. More than 100 medications available in Europe, Canada, Australasia and the Middle East are not currently approved by the US-FDA and hence do not have a pregnancy risk categorization. Most practitioners believe that the availability of pregnancy risk categorization is extremely important to the health care practitioner when prescribing, dispensing, or administering medications to pregnant women.
The aim of this review is to evaluate the foetal risk associated with non-US-FDA approved medications currently registered by the Saudi Food and Drug Authority (S-FDA). The medications will be further categorized according to the US-FDA pregnancy risk categorization system based on the available literature. It is important to note that the proposed risk categorization is neither official nor is endorsed by the US-FDA and it is solely based on expert opinion.
Materials and methods
We identified all non-US-FDA approved medications registered in the Saudi National Formulary (SNF) by the S-FDA as of October 2007. These medications are also approved by other drug regulatory authorities, including Canada, Europe, and Australia but are not assigned a pregnancy risk category. A total of 114 medications were identified of which 93 were considered eligible for evaluation. The criterion for inclusion was any medication not approved by US-FDA. Twenty-one medications were excluded for different reasons, e.g., herbal products, medications withdrawn from the market, or medications for veterinary use only. A thorough literature evaluation was performed to identify any associated risk with the use of the previously identified medications during any stage of pregnancy. Evaluated outcomes included any functional or anatomical birth, or embryocidal effects. Both immediate and delayed effects were considered for this review. Effects on fertility were excluded.
Three clinical pharmacists (the authors of this manuscript) recommended a US-FDA pregnancy risk category (Table 1) for each medication after reviewing all available literature. An algorithm was developed based on the US-FDA categorization ( Fig. 1 Either animal studies did not show a risk to the foetus and no controlled human studies are available, or animal studies showed an adverse effect on the foetus but well-controlled clinical trials in pregnant females have failed to demonstrate a risk to the foetus C Animal studies have shown teratogenic or embryocidal effects, but there are no controlled clinical trials in females, or no studies are available in either animals or humans D Positive evidence of foetal risk exists in humans, but benefits in certain situations may justify the use of the drug despite its risks (e.g., life-threatening situations or in cases where safer drugs cannot be used or are ineffective for treatment of serious diseases) X Studies in animals or humans have shown foetal abnormalities or there is evidence in humans of foetal risk, or both, and the risk outweighs any possible benefit Human data showed no signs of pathological development or myocardial dysfunction in children whom mothers received it as tocolytic in late trimester. However, one case of supra-ventricular arrhythmia was reported (D'Hooghe and Odendaal, 1991; Trittenwein et al., 1986; Wilk, 1985) Animal studies showed no evidence of teratogenicity in rats but an increase in stillborn with no dysmorphogenic effects in rabbit was seen ( In humans, a pharmacokinetic study in small number of patients (5) who were given ornidazole showed no increased in teratogenicity (Bourget et al., 1995) No animal data were found Oxethazaine, oxythazaine (Mucaine Strocain)
Local anaesthetic; anticholinergic A3rd
A double blind comparative study of oxethazaine and placebo in 50 patients with symptoms of heartburn during late pregnancy showed no adverse effects on pregnancy outcomes (Kovacs et al., 1990) No animal data were found Pinaverium bromide (Dicete)
Calcium channel blocker C
A letter to the editor reported 10 pregnant women who inadvertently took pinaverium due to prescription errors. Only one pregnancy miscarriage occurred and the remainder resulted in normal babies (DRUGDEXÒ, Einarson et al., 1999) No animal data were found Piracetam ( Antimicrobial; macrolide A In 9 reported cases, roxithromycin did not show any teratogenicity Roxithromycin does not appear to be a major teratogen in a prospective study where 183 women with first trimester exposure to roxithromycin were followed through delivery and no adverse developmental effects were identified. Studies in animals have not shown evidence of an increased risk of foetal defects (DRUGDEXÒ, Czeizel et al., 2000; Tellem et al., 2005; Chun et al., 2006; Paulus et al., 2005) FDA pregnancy risk category for other macrolides is (B) for Azithromycin and erythromycin while it is (C) for clarithromycin (Briggs et al., 2005 In one human study, there were 13 (57%) spontaneous abortions in the sodium stibogluconate monotherapy group and none in either of the other two groups (Ambisome and sodium stibogluconate and ambisome alone) (Mueller et al., 2006) No animal data were found Sulpiride (Dogmatil, Genprid)
Antipsychotic agents C In pregnant women who took sulpiride; the drug concentrations in maternal plasma in late pregnancy and postnatally and in umbilical cords were almost the same, which mean they were freely transferred from mothers to babies In animals, administration of sulpiride to pregnant rats was associated with increased risk of foetal hyperprolactinemia and increased growth (DRUGDEXÒ, Yoshida and Yamashita, 2003) Teicoplanin (Targocid) Antimicrobial; miscellaneous C No human data were found Animal studies have not shown teratogenic effect (DRUGDEXÒ) Tenoxicam (Tenox) NSAID C When studied in a small group of women who were undergoing caesarean section, a single intravenous 20-mg dose of tenoxicam given 10 min before induction of anaesthesia reduced postoperative need for pain medication without notable adverse effects on mother or foetus (DRUGDEXÒ, Elhakim and Nafie, 1995) No increase in congenital anomalies when tested in mice, rats, and rabbits; however, an increase in embryo death was seen in rabbits at the top dose used (32 mg per kg per day). The highest doses used in mice and rats were 4.8 and 12.0 mg per kg per day; respectively. FDA pregnancy risk category for other NSAIDs is (C) and (D) in 3rd trimesters (Briggs et al., 2005 ) Thiamphenicol (Thiophenicol) Antimicrobial; broad Spectrum
C
No human data were found. In one animal series, the frequency of congenital anomalies was no greater than expected among the offspring of mice or rats treated during pregnancy with thiamphenicol in doses; respectively, 1-33 and 1-3 times those used clinically. Foetal loss occurred at the higher doses that were toxic to the mothers. In contrast, another study showed an increased frequency of skeletal malformations among the offspring of rats treated with double the usual human dose very early in pregnancy (DRUGDEXÒ). Tianeptine (Stablon) Antidepressant; serotonin reuptake facilitator C No animal or human data were found Tiapride, Tiapridum (Tiapridal) Dopamine (D 2 ) antagonist C No human data were found One group studied tiapride in rats using up to 500 mg per kg doses during organogenesis or from day 17 until 3 weeks after birth. No teratogenicity was found but there was slight retardation of postnatal growth (DRUGDEXÒ) Tiaprofenic acid (Surgam) NSAID C No human data were found No teratogenic effects were found during animal studies but parturition was delayed and prolonged (Saudi Food and Drug Authority. SPDI, 2008; EMC, MHRA, BNF, DRUGDEXÒ) FDA pregnancy risk category for other NSAIDs is (C) and (D) in 3rd. trimester (Briggs et al., 2005) (Briggs et al., 2005) , Pubmed/Medline. The Pubmed and Medline were searched from 1960 to December 2008 with no language restrictions using the following search terms: drug name, pregnancy, functional or anatomical birth defects, embryocidal effect, and teratogenicity. A single risk category was assigned to each medication according to the evaluated data. More than one risk level was assigned for medications with a different risk at different trimesters. Furthermore, the US-FDA category for similar medication(s) was added whenever it differed from the assigned category designated by the authors. Disagreements were resolved by consensus. Foetal risk assessment for all medications was summarized according to the available data. All 93 medication package inserts were reviewed to identify whether the manufacturer has formal pregnancy prevention risk-management strategies to direct clinicians and/or patients (e.g., frequency of pregnancy testing or number and type of contraception methods). We attempted to summarize the evidence from animal as well as human data (case reports, case series, pregnancy registries or post-marketing surveillance) pertaining to the identified effect on pregnancy outcomes for each of the included medications.
Results
The literature search results for 93 medications are summarized in Table 2 . Sixty-nine medications (73%) were judged by the authors to be category risk C. Of these the risk categorization of 32 medications was based only on animal studies. Eight medications had published human data and 29 medications had neither human nor animal data.
Ten medications were assigned category risk D (10.6%). Medications classified as category risk D belong to the following groups: benzodiazepines, anti-androgens, androgen steroids, anti-thyroids, antimicrobials, dopamine antagonists, antidepressants, anticonvulsants, oestrogen and progesterone derivatives, antineoplastics, and analgesic agents. Twelve medications (12.7%) were assigned category risk B including histamine agonists, haemorrhoid preparations, antimicrobials, antihistamines, ergot derivatives, antiprotozoals, antipsychotics, dopamine agonists, antioxidants and two anticholinergic medications. Roxithromycin, oxethazaine, and diosmin were the only medications assigned category risk A based on the available evidence.
Among the 93 medications' package inserts that were reviewed to identify any pregnancy prevention risk management strategies recommended by the manufacturer, 7 medications had no information on the use during pregnancy in the package inserts. None of the 93 medications had a formal pregnancy risk management system. Ten medications (bezafibrate, bromazepam, bromhexine ''in the first trimester'', clobutinol, cyproterone, deferiprone, quinagolide, sodiumstibogluconate, tianeptine, tiaprofenic acid ''in the first trimester'') had clear statements indicating that women should be counselled to take contraceptive measures. The statements also indicated that women should be advised to immediately stop taking the medication should they become pregnant or plan to become pregnant. The remaining medications had general statements that women should consult their physician or pharmacist if they are pregnant or planning to become pregnant. 
Discussion
The decision to prescribe a medication during pregnancy involves multiple factors that include molecular weight of the drug, whether the drug crosses the placenta, pregnancy trimester (gestational age), and the necessity to use the prescribed medication during pregnancy. Usually, a benefit of using the medication against any possible risk to the mother or the foetus is undertaken during this process. A thorough understanding of these benefits and risks is mandatory before prescribing. Current regulatory requirements for assessing the risk of teratogenicity of new medications do not mandate human studies. This is understandable as it would be unethical to include pregnant women who are typically excluded from all stages of preapproval clinical trials. The only available two methods for assessing teratogenicity of drugs in humans are case series and pregnancy registries (e.g., Pregnancy Exposure Registries available in Women's Health Research).
Currently, four countries have developed a pregnancy risk categorization for marketed pharmaceuticals. Australia, Germany, Sweden, and the United States have their own pregnancy risk categorization which is mainly based on the availability of evidence that supports safety or teratogenicity during pregnancy. In 1979, the US-FDA developed a classification of foetal risks for marketed medications (Table 1) . This was based on a similar system that was introduced in Sweden one year earlier. The currently used US-FDA pregnancy risk categorization has been criticized by many clinicians and researchers as insufficient to determine drug safety accurately during pregnancy. The Teratology Society (http://www.teratology.org) has called for a change in pregnancy labelling for medications as the current classification does not adequately communicate risk of reproductive and developmental toxicity. In addition, the categories do not discriminate among potential developmental adverse effects based on severity, frequency, or type. They do not adequately address the full range of potential developmental drug effects including foetal death, structural malformations, alterations in foetal growth, and functional deficits (Buhimschi and Weiner, 2009 ; Public Affairs Committee of the Teratology Society, 2007). In 2008, the US-FDA proposed major revisions to the labelling of prescription drugs (including biological products) to provide better information about the effects of medications used during pregnancy and breastfeeding (FDA News). Worth mentioning, that it has been almost three years since the publication of the initial proposal and until now it has not been finalized. Until the time of writing this manuscript the US-FDA still uses the current pregnancy risk categorization for newly approved medications and continues to change the pregnancy risk levels assigned to certain approved medication.
There is scant information on pregnancy outcomes of many of the non-US-FDA approved medications. Often, the safety of similar drugs cannot be determined until they have been widely used. The medications reviewed in this study are not marketed in the United States; therefore, they are not assigned a pregnancy risk categorization by US-FDA. In addition, there is inadequate information on teratogenicity of currently approved drugs in the US to determine risk-benefit ratio before prescribing (Lo and Friedman, 2002) . Moreover, despite the fact that the currently used categorization system by the US-FDA does not accurately determine foetal safety, and due to the lack of a better locally or internationally endorsed system by regulatory bodies in the country we believe that the US-FDA pregnancy risk categorization is the most commonly used system by clinicians in practice in Saudi Arabia.
In this review, we attempted to categorize all non-US-FDA approved medications in Saudi Arabia up until October 2007 according to the non-US-FDA pregnancy risk categorization system based on the current available evidence. We also summarized the evidence from animal and human data (case reports, case series, pregnancy registries or post marketing surveillance) pertaining to their effect on pregnancy outcomes for each of these medications. To our knowledge, this is the first attempt to assess and analyse the foetal risk for previously uncategorized non-FDA approved medications.
The importance of this analysis stems from the fact that despite the criticism the US-FDA classification has received, clinicians from different countries still depend on this classification almost exclusively when prescribing, discontinuing, or substituting medications during pregnancy (Buhimschi and Weiner, 2009 ; Public Affairs Committee of the Teratology Society, 2007). Furthermore, this assessment could be used as a starting point for clinicians in other countries such as Europe, Canada and Australia to evaluate the pregnancy risk of non-US-FDA approved medications used by their patients.
Our results showed that the pregnancy risk category figures assigned in this review were comparable to the figures currently assigned by the US-FDA to marketed drugs based on previously published reports. The majority of the reviewed medications were assigned category C (73%) and this approximates the US-FDA data in which about 60% of the medications belong to this category (Uhl et al., 2002) . Since the majority of medications have data on their teratogenicity only in animals but not humans or they have no data whatsoever, this was expected. This finding has been cited and discussed by previous investigators and was attributed to less active post-marketing surveillance (Adam et al., 2011) . It is of note that similarity between the two figures is not meant to validate our proposed classification.
When reviewing the package inserts of these medications, inconsistencies in defining the foetal risk for specific medication was apparent. In addition, only few drugs had specific pregnancy prevention risk-management strategies to direct the clinician and/or patient. This analysis demonstrates the urgent need for both consistency in the description of the foetal risk within the medication package insert and in the recommendations by the manufacturer for specific and formal pregnancy prevention risk-management programs.
The main limitation of this analysis is that it comes from an independent group which did not have access to drug manufacturers' on-file data. We also performed only Medline search and did not include EMBASE and other databases for primary literature search.
Conclusion
Our results showed comparable figures of pregnancy risk category to the currently US-FDA approved medications based on available data. Inconsistencies in defining and reporting the foetal risk category/assessment among different drug regulatory authorities would create confusion and affect the prescribing decision pattern. We believe that standardization and inclusion of this information in medications package inserts are extremely important to all health care practitioners.
